This study is testing a new treatment called **XH001 injection**, which is a personalized mRNA tumor neoantigen vaccine. It's used with standard adjuvant treatment, which is extra treatment given after surgery to lower the risk of cancer returning. The study focuses on patients with high-risk solid tumors like pancreatic or liver cancer after they've had surgery.

Researchers want to see if this treatment is safe and if it helps the immune system fight cancer better by checking the **T-cell response**. T-cells are part of the immune system that help fight infections and diseases like cancer. They also want to know if this treatment helps patients stay cancer-free longer.

• The study is for people aged 18-70 who have had surgery for high-risk solid tumors.
• Participation involves checking for side effects and how well the treatment works.
• Participants should not have other major health issues or prior similar treatments.